Clinical Trial: Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Blast Phase Refractory to Imatinib Mesylate (STI 571)
Brief Summary: To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
Detailed Summary:
Sponsor: Astex Pharmaceuticals
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Astex Pharmaceuticals
Dates:
Date Received: July 19, 2002
Date Started: July 2002
Date Completion:
Last Updated: January 22, 2013
Last Verified: June 2008